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Abstract
The cyanide metabolite 2-aminothiazoline-4-carboxylic acid (ATCA) is a promising biomarker for cyanide exposure because of its stability
and the limitations of direct determination of cyanide and more abundant cyanide metabolites. A simple, sensitive, and specific method
based on derivatization and subsequent gas chromatography–mass spectrometry (GC–MS) analysis was developed for the identification and
quantification of ATCA in synthetic urine and swine plasma. The urine and plasma samples were spiked with an internal standard (ATCA-d2 ),
diluted, and acidified. The resulting solution was subjected to solid phase extraction on a mixed-mode cation exchange column. After elution
and evaporation of the solvent, a silylating agent was used to derivatize the ATCA. Quantification of the derivatized ATCA was accomplished
on a gas chromatograph with a mass selective detector. The current method produced a coefficient of variation of less than 6% (intra- and
interassay) for two sets of quality control (QC) standards and a detection limit of 25 ng/ml. The applicability of the method was evaluated by
determination of elevated levels of ATCA in human urine of smokers in relation to non-smokers for both males and females.
© 2005 Elsevier B.V. All rights reserved.
Keywords: Cyanide; 2-Aminothiazoline-4-carboxylic acid; GC–MS; Chemical warfare agent

1. Introduction
Exposure to cyanide can occur by a number of scenarios, including the use of cyanide as a chemical warfare agent
(CWA) [1–5]. The analysis of biological matrices, specifically urine and blood, to verify exposure to cyanide is important to determine past exposure to cyanide [1,5]. Due
to its volatility, hydrogen cyanide rapidly dissipates from
open areas. Therefore, biological fluids of persons or animals exposed to hydrogen cyanide may be the only repository of evidence that cyanide was used as a CWA. As
∗
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seen in Fig. 1, three major markers of cyanide exposure appear in the blood or urine of exposed individuals: cyanide
ion (CN− ), thiocyanate (SCN− ), and 2-aminothiazoline-4carboxylic acid (ATCA) or its tautomer 2-iminothiazolidine4-carboxylic acid (ITCA).
Although many sensitive methods exist for analysis of
cyanide ion [6], they all suffer from the practical limitations that stem from cyanide’s volatility and nucleophilic nature. Under normal physiological conditions, cyanide (pKa
9.2) is protonated. This protonated form of cyanide is extremely volatile [5,7], which contributes to its elimination
from analytical samples. The nucleophilic nature of the nonprotonated form of cyanide also contributes to its elimination
from biological media. Therefore, depending on the route
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Fig. 1. Cyanide metabolism and major modes of release. Adapted from
Baskin et al. [6]. A proposed mechanism for the formation of ATCA from
the reaction of cyanide with cystine is presented by Nagasawa et al. [16].

and duration of exposure, cyanide is typically eliminated
from blood within 20 min post-exposure [5,7,8]. In addition to rapidly decreasing concentrations in biological fluids,
cyanide sometimes forms as an artifact of storage conditions
in a variety of biological samples, including blood [9–11].
Cyanide exhibits variable concentrations in biological fluids
depending on the route of exposure (e.g., oral versus inhalation) [12] and has significant endogenous (inherently present)
concentrations. Some sources of endogenous cyanide include
normal metabolism of amino acids within the body along with
external sources such as smoking, inhalation of smoke from
fires, and some types of food [5]. Because of these limitations,
analytical determination of cyanide metabolites is generally
more advantageous to direct cyanide determination. It should
be noted that the metabolites of cyanide should also exhibit
significant endogenous concentrations, originating from the
same sources of endogenous cyanide.
Thiocyanate is the major metabolite of cyanide, and a
number of sensitive methods are available for its measurement in biological fluids [6]. Thiocyanate has many advantages as a marker for cyanide exposure. It is non-volatile
and can be analyzed in blood, urine, and saliva. However,
thiocyanate does have some disadvantages as an indicator of
cyanide exposure. Ballantyne [10] found that analytical recovery of thiocyanate from whole blood is not quantitative
and thiocyanate concentrations in blood varied inconsistently
during storage at various temperatures over a period of 2
weeks. Isom and Baskin [13] also noted that thiocyanate may
be formed by other modes of metabolism besides cyanide intoxication or metabolism.
While there are numerous sensitive analytical techniques
to determine both cyanide and thiocyanate in biological fluids, very few techniques exist to analyze for ATCA. In fact, the
liquid chromatographic analytical technique of Lundquist et
al. [14] and the spectrophotometric method of Wood et al. [15]

are the only available methods for determination of ATCA in
biological fluids. ATCA accounts for approximately 20% of
cyanide metabolism and increases as exposure increases [5].
ATCA is formed when cyanide reacts with l-cystine through
a proposed intermediate, ␤-thiocyanoalanine, that is subsequently transformed to ATCA (Fig. 1) [16]. ATCA may be
present as a tautomer between itself and 2-iminothiazolidine4-carboxylic acid (ITCA). The structure of ATCA resembles
a cyclic amino acid and appears to have the same general
properties as an amino acid with similar functional groups.
ATCA may be an excellent marker for indicating cyanide exposure primarily because of its stability. It is stable for months
in biological samples at freezing and ambient temperatures
[14]. The structure of ATCA also lends itself to simple but
extremely effective sample preparation and derivatization.
ATCA represents an alternative metabolite of cyanide exposure, and a simple assay for ATCA may circumvent the disadvantages of cyanide and thiocyanate analysis. Therefore,
the objective of this study was to develop a novel analytical method to determine ATCA concentrations in urine and
plasma for the purpose of simple and accurate verification of
exposure to cyanide.

2. Experimental
2.1. Reagents and standards
All chemicals and solvents were at least HPLC grade.
ATCA (l-2-aminothiazoline-4-carboxylic acid) was obtained
from Chem-Impex International (Wood Dale, IL, USA). A
standard stock solution (100 g/ml) was prepared in 0.1 M
HC1 and used throughout the current study. An aqueous ammonium hydroxide solution (approximately 50%) was used
to prepare elution solvents. Oasis® MCX (mixed-mode cation
exchange) columns were obtained from Waters Corporation
(Milford, MA, USA). The derivatizing agent N-methyl-Ntrimethylsilyl-trifluoroacetamide (MSTFA) was purchased
from Pierce Chemical Company (Rockford, IL, USA). All
solvents were purchased from Sigma–Aldrich (St. Louis,
MO, USA). Deuterated ATCA (ATCA-d2 ) was obtained from
the lab of Dr. Herbert T. Nagasawa (Department of Veterans
Affairs Medical Center, Minneapolis, MN, USA) prepared
by reaction of deuterated l-cysteine (3,3-d2) with cyanamide
[16].
2.2. Biological ﬂuids
Synthetic urine and swine (Sus scrofa) plasma were used
to optimize analytical methodologies and sample preparation techniques. The use of synthetic urine as a sample matrix
was necessary due to endogenous concentrations of ATCA in
urine. The synthetic urine was prepared as a 1 kg stock solution according to Inn et al. [17] with chemicals obtained from
Sigma–Aldrich (St. Louis, MO, USA), TCI (Tokyo Chemical International, Tokyo, Japan), and Acros Organics (Mor-
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ris Plains, NJ, USA). Swine plasma (non-sterile with EDTA
anti-coagulant) was purchased from Pel-Freez Biologicals
(Rogers, AR, USA).
Urine and blood samples from human (Homo sapiens)
subjects, age 21–50 years, were used to evaluate the applicability of the analytical method. Urine samples were used
to determine if a significant difference in ATCA concentration could be found in the urine of smokers relative to nonsmokers. Smokers consume small amounts of cyanide from
the inhalation of cigarette smoke. Therefore, ATCA concentrations in the urine of smokers should be elevated relative
to non-smokers. The number of samples used for this study
totaled 40 with 23 males and 17 females. Volunteers donated
urine in the morning in sterile urinalysis cups that were subsequently stored at 4 ◦ C until analyzed. All samples were
analyzed less than 14 days after they were gathered. No personal information was recorded from the volunteer donors
except their gender and whether they were a smoker. Plasma
was obtained from male non-smokers to determine whether
endogenous levels of ATCA could be detected by the current method. Plasma from smokers was not analyzed for the
current study.
2.3. Sample preparation
Urine samples were diluted, acidified, and passed through
a mixed-mode cation exchange column to prepare the samples for gas chromatography–mass spectrometry (GC–MS)
analysis. Specifically, 100 L, of sample (spiked synthetic
urine, human urine, spiked swine plasma, or human plasma)
was diluted with 900 L of 0.1 M HC1 to ensure the ATCA
was positively charged (pH < 1). ATCA-d2 (100 ng/ml) was
added to the diluted sample as an internal standard. This
diluted sample was then aspirated through an MCX column, after conditioning with successive washes of 1 ml each
methanol and H2 O. The column was then washed successively with 1 ml each of 0.1 M HC1 and 100% methanol.
The ATCA was eluted from the columns using 1 ml of
CH3 OH:NH4 OH:H2 O (50:25:25) into 2 ml micro-centrifuge
tubes. HC1 (200 L of 0.1 M) was added to the centrifuge
tubes to decrease the pH of the sample (pH < 11) prior to drying (the ring in ATCA may open under heat and basic conditions [14]). The sample was dried completely in a centrifugal
evaporation system (Labconco, Kansas City, MO, USA) at
40 ◦ C. The dried samples were derivatized with 150 L of
30% MSTFA in hexane for 60 min at 50 ◦ C in capped centrifuge tubes to produce the trimethylsilyl (TMS) derivative of
ATCA as illustrated in Fig. 2. The sample was then transferred
with borosilicate transfer pipets to GC–MS autosampler vials
fitted with 200 L deactivated glass inserts.
2.4. Gas chromatography–mass spectrometry
Analysis was performed on an Agilent GC–MS system
consisting of a 6890N Series II gas chromatograph, a 5973 series mass-selective detector, and a 7683 auto-sampler. A DB-
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Fig. 2. Derivatization reaction of ATCA with MSTFA. TMS, trimethylsilyl
group Si(CH3 )3 . Inset: ATCA-d2 chemical structure.

5 MS bonded phase column (30 m × 0.25 mm I.D., 0.25 m
film thickness; J&W Scientific, Folsom, CA) was used with
helium as the carrier gas at a flow rate of 0.8 ml/min and column head pressure of 52.4 kPa (7.6 psi). The auto-sampler
introduced a 1 L sample into an injection port with a total inlet flow of 54 ml/min. The injection port was held at
290 ◦ C and contained an Agilent inlet liner of deactivated
borosilicate single-taper with glass wool packing. The purge
flow was initiated at 1 min with a flow of 50 ml/min. The
GC oven temperature was initially held at 100 ◦ C for 1 min,
then elevated at a rate of 15 ◦ C/min up to 230 ◦ C. The gradient was then increased to 30 ◦ C/min up to 300 ◦ C where
it was held constant for 1 min. This gradient resulted in an
overall run time of 13 min with ATCA-(TMS)3 eluting at approximately 8.76 min. The GC was interfaced with a massselective detector with the transfer line held at 265 ◦ C. Fragmentation of the sample was accomplished through electron
impact with selected ion monitoring (SIM) mode for monitoring abundant ions of ATCA (m/z 245, 347, and 362) and
ATCA-d2 (m/z 349, and 364) with a dwell time of 100 ms
each. The MS conditions were as follows: ion source pressure 2.0 mPa (1.5 × 10−5 Torr), source temperature 230 ◦ C,
quadrupole temperature 150 ◦ C, electron energy 70 eV, electron emission current 34.6 A, and electron multiplier voltage +400 relative to the autotune setting.
2.5. Calibration and quantiﬁcation
Calibration and quality control (QC) standards were
prepared from the stock ATCA solution in the range of
10–2000 ng/ml by diluting in synthetic urine. Calibration
standards were prepared with concentrations of 10, 20, 50,
100, 200, 500, 1000, and 2000 ng/ml. The 2000 ng/ml standard was found to be above the upper limit of quantification
(ULOQ) for the method, and the 10 and 20 ng/ml standards
were below the lower limit of quantification (LLOQ). A percent relative standard deviation of less than 10% and a percent

240

B.A. Logue et al. / J. Chromatogr. B 819 (2005) 237–244

deviation of less than ±20% back-calculated from the nominal concentration for each calibration standard were used as
criteria for determining the ULOQ, LLOQ, and the linear dynamic range. QC standards (n = 5) were prepared at 150 ng/ml
and 800 ng/ml. Intraassay studies were performed by analysis of five replicate QC standards at 150 and 800 ng/ml during
1 day and interassay studies were performed by analysis of
these same quintuplicate QC standards on 3 different days
(within 1 week). The intraassay studies were designed to determine the stability of the method for a single analysis (i.e.,
construct a calibration curve and analyze the QC standards to
validate the method for that analysis). The interassay studies
were designed to evaluate the stability of the method for a
number of days of analysis (i.e., construct three calibration
curves on 3 separate days and analyze the same QC standards
for each calibration curve to validate the method for multiple
analyses).
2.6. ATCA stability
All stability experiments were performed on samples of
1000 ng/ml ATCA in synthetic urine. Short-term stability experiments included evaluation of the stability of ATCA during multiple freeze-thaw cycles, stability of ATCA on the
bench-top, and stability of TMS-derivatized ATCA in the
autosampler. Freeze-thaw stability was determined by completing five freeze-thaw cycles with analysis of ATCA after
each individual cycle. For verification of bench-top stability,
a urine sample was spiked with ATCA and allowed to stand
at room temperature. The spiked sample was analyzed at 0,
1, 2, 4, 8, and 24 h. For the autosampler stability experiment,
eight sets of samples (each in triplicate) were derivatized,
placed in the autosampler, and analyzed at approximately 1,
4, 7, 9, 12, 15, 18, and 20 h post-derivatization to determine
the stability of the TMS derivatized ATCA.
Experiments were also undertaken to determine the longterm stability of ATCA under typical storage conditions. Five
long-term stability samples were prepared with a range of
normal urinary pH values (4, 6, and 8) [18] and stored at 4,
−20, and −70 ◦ C. Three aliquots of these samples were analyzed prior to storage. The samples were then stored for 3
months with analysis at the end of each month. Three replicates of each sample were analyzed for each sampling period.
For example, at the end of the 2nd month, samples were removed from storage and allowed to thaw if necessary, three
aliquots of each sample were removed and analyzed, and the
samples were placed back into storage.
2.7. Assay selectivity and recovery
The selectivity of the assay was determined by comparison
of multiple blank samples of synthetic urine and swine plasma
to determine the potential for interfering (unresolved) background peaks that co-elute with the ATCA-(TMS)3 . To determine recovery, an aliquot of ATCA was spiked into synthetic
urine or swine plasma for a final concentration of 1000 ng/ml.

The sample was then prepared and analyzed as above. The
recovery of ATCA was calculated as a percentage by dividing
the recovered ATCA concentration by the nominal concentration added to the urine or plasma.
2.8. Data analysis
Calibration was performed by plotting peak area ratios
of the characteristic ions of ATCA (m/z 362) and the internal standard, ATCA-d2 (m/z 364) as a function of the spiked
ATCA concentration. A weighted (1/x2 ) linear fit was employed for all calibration curves. Precision was calculated
as a %CV by dividing the standard deviation of the peak
area ratios by the mean peak area ratio. The accuracy was
calculated as a percentage by dividing the mean calculated
concentration by the intended concentration. Precision and
accuracy were calculated for each set of QC standards (for
intra- and interassay evaluation). Data from long- and shortterm stability experiments were handled by determination of
ATCA concentrations as a percentage of a positive control.
Stability is represented by a percent difference from the positive control. For the stability experiments, positive controls
were freshly prepared control samples with the same nominal concentration of ATCA as the sample to be analyzed.
Comparison of the urine samples for significant differences
in the ATCA concentrations of smokers compared with nonsmokers was accomplished by a two-tailed t-test. Comparison of the four groups of volunteers (female non-smoker,
female smoker, male non-smoker, and male smoker) was accomplished by an analysis of variance and the Bonferroni,
Tukey, and Newman–Keuls multiple range tests to identify
significant differences between the identified subsets of volunteers.

3. Results and discussion
3.1. Sample preparation and GC–MS analysis
ATCA has a basic amine moiety and an acidic carboxylic
acid moiety (Fig. 1). The amine is positively charged at neutral to low pH values and the carboxylic acid is negatively
charged at medium to high pH values. Therefore, either the
amine, the carboxylic acid, or both are charged at all aqueous
pH values. The sample preparation scheme was developed
to take advantage of the positively charged amine at low pH
values. Samples were acidified and mixed-mode cation exchange columns were used to electrostatically bind the positively charged ATCA on the column while allowing neutral
and negatively charged compounds through the column. A
basic solvent was used to neutralize the amine and release it
from the cationic sorbent.
After sample preparation, ATCA must be derivatized to
analyze by GC–MS because it is non-volatile. ATCA was
derivatized with MSTFA, which can react with primary and
secondary amines and carboxylic acid moieties, replacing
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Fig. 3. Electron impact mass spectrum of trimethylsilyl (TMS) derivatized
ATCA and abundant ions. Ions with a mass-to-charge ratio of 245, 347, and
362 were monitored to analyze for ATCA in urine samples. The large 73 m/z
ion above corresponds to one TMS fragment. Inset: Structure of derivatized
ATCA with abundant fragments indicated.

exchangeable hydrogens with TMS groups. Fig. 2 illustrates
the chemical structure of ATCA and the most likely product
of derivatization with MSTFA. Inset is the structure of the
internal standard (ATCA-d2 ).
Fig. 3 illustrates the mass spectra of derivatized ATCA.
The mass-to-charge ratio of 362 corresponds to the molecular ion of the ATCA-(TMS)3 . The probable fragmentation
of the ATCA-(TMS)3 derivative (corresponding to ions 347,
316, and 245 m/z) is also illustrated. Fig. 4 shows a representative chromatograph of both a blank synthetic urine sample
(0 ng/ml ATCA, lower trace), a spiked synthetic urine sample
(1000 ng/ml ATCA, upper trace), and a human urine sample
(middle trace). Fig. 5 shows a representative chromatograph
of blank human plasma (0 ng/ml ATCA, lower trace) and
a spiked human plasma sample (1000 ng/ml ATCA, upper
trace).
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Fig. 4. Chromatographs of non-spiked synthetic urine (lower trace),
1000 ng/ml ATCA spiked into synthetic urine (upper trace), and non-spiked
human urine (middle trace). The human urine was sampled from a male
non-smoker. The human urine was sampled from a male non-smoker with
a peak area corresponding to an ATCA concentration of 225 ng/ml. The
chromatographs represent the sum of the individual ions gathered in SIM
mode after sample preparation of the urine samples with SPE and derivatization. No internal standard was added to the urine samples prior to analysis.
ATCA-(TMS)3 elutes at approximately 8.76 min.

3.2. Linearity and dynamic range
Calibration curves were constructed in the range of
50–1000 ng/ml ATCA with five concentrations, each in triplicate, in addition to five blank samples (0 ng/ml ATCA, nominal concentration) for 3 separate days. The data were best
described by a weighted (1/x2 ) linear least squares fit of the
calibration samples. The best model was determined by analysis of the weighted sum-of-squares and the absolute relative
error for each model. The dynamic range for the method was
50–1000 ng/ml ATCA, and the limit of detection was found
to be 25 ng/ml with 3 separate days of validation when calculated at a signal-to-noise ratio of 3 (n = 5 for each day).
It should be noted that an internal standard with only two
deuterium atoms may result in overestimation of internal

Fig. 5. Chromatographs of non-spiked human plasma (lower trace) and
spiked human plasma (upper trace). The plasma was sampled from a male
non-smoker. The chromatographs represent the sum of the individual ions
gathered in SIM mode after sample preparation of the urine samples with
SPE and derivatization. No internal standard was added to the plasma samples prior to analysis. ATCA-(TMS)3 elutes at approximately 8.76 min.
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Table 1
Quality control data for ATCA analysis by GC–MS in synthetic urine
Nominal concentration (ng/ml)

Intraassay
accuracy (%)a

150
800

105–100
99.0–97.4

a
b

Interassay
accuracy (%)b

103
98.0

Intraassay
precision (%CV)a

Interassay
precision (%CV)b

<4.1
<3.0

5.3
5.8

Mean of 1 day of validation (n = 5 for each day; overall range is for 3 separate days).
Mean of 3 days of validation (n = 15).

standard peak areas, particularly when analyte concentrations
are large [19]. This potential problem was accounted for by
developing a calibration curve that excluded calibrators with
a percent deviation of less than ±20% from the nominal concentration. If the internal standard area is overestimated, the
ratio of analyte to internal standard would decrease, and therefore increase the percent deviation of the calibrator from its
nominal concentration. If the overestimation becomes large
enough for a particular concentration, that calibration standard would be excluded from the curve. For practical purposes, if analyte concentrations are above the ULOQ of the
calibration curve (i.e., overestimation of the internal standard
concentration is occurring), dilution of the sample or use of
a smaller sample volume and reanalysis could be performed.
Alternatively, the curve could be reconstructed with an increased internal standard concentration.

urine, direct experimental evidence of excellent selectivity in
human plasma was gathered (Fig. 5).
The recovery of ATCA was probed in spiked plasma and
urine samples. The recovery of ATCA was 84% (n = 6) and
100% (n = 6) for synthetic urine and swine plasma samples,
respectively. No matrix effects were observed except when
the post solid-phase extraction column addition of 0.1 M
HC1 was omitted from the analytical procedure. When this
step was omitted, the absolute ATCA-(TMS)3 signal was decreased. It should be noted that the internal standard did correct for this effect. It should also be noted, that the selectivity
and recovery of ATCA from human urine or plasma may be
different than that found during experiments using synthetic
urine and the swine plasma because they are surrogate matrices and can only approximate human urine and plasma.
3.5. Short- and long-term stability

3.3. Accuracy and precision
The intra- and interassay accuracy and precision are reported in Table 1 for the two QC samples. The accuracy
and precision reported in Table 1 indicate that the method
is extremely precise and also accurate for the concentrations
tested. The ranges of percent relative standard deviation of the
calibrators for the ULOQ (1000 ng/ml) and LLOQ (50 ng/ml)
were 1.5–2.0% and 0.42–8.0%, respectively (n = 3 per day,
for 3 days; data not shown). The ranges of percent deviation
back-calculated from the nominal concentration of the calibration standards for the ULOQ and LLOQ were 92–94%
and 91–96%, respectively (n = 3 per day, for 3 days; data not
shown).

Both the short- and long-term stability of ATCA were
found to be excellent, with Table 2 illustrating that none of
the samples deviated from the control by more than ±9.3%
over the course of all stability experiments. The stability of
ATCA was validated in synthetic urine for 24 h on the benchtop, through 5 freeze-thaw cycles, and for 3 months at 4, −20,
and −70 ◦ C and pH values of 4, 6, and 8. Stability of the TMS
derivatized ATCA was also demonstrated by analysis of the
derivative with increasing periods of storage at room temperature after derivatization. The largest deviation from the
Table 2
Short- and long-term stability of ATCA in synthetic urine
Stability

3.4. Assay selectivity and recovery
Assay selectivity is demonstrated by the absence of interfering peaks in the total ion chromatograph. In Fig. 4, the
ATCA-(TMS)3 peak elutes at approximately 8.76 min and
the blank synthetic urine has little background signal over
the time where ATCA-(TMS)3 elutes from the column. The
ATCA-(TMS)3 peak also elutes during a region where there is
little background signal from the plasma (Fig. 5). Therefore,
the selectivity of the method was adequate for both plasma
and urine. Over twenty samples of blank (non-spiked) synthetic urine were analyzed to demonstrate assay specificity
and selectivity. Although surrogate samples were used for

Stability
experiment

Greatest deviation
from control (%)a

Short-termb

Autosamplerc
Benchtop
Freeze-thaw

2.8
4.0
8.9

Long-termb

pH 4, 4 ◦ C
pH 6, 4 ◦ C
pH 8, 4 ◦ C
pH 6, −20 ◦ C
pH 6, −70 ◦ C

9.3
5.6
−6.8
−5.8
4.4

a The deviation of each individual sample from the positive control was
calculated and the largest deviation is reported.
b Samples for long-term stability were analyzed for 3 months. Short-term
stability was determined over 20 h for autosampler stability experiments,
24 h for benchtop stability experiments, and over five freeze-thaw cycles.
c Stability of TMS derivatized ATCA at room temperature.
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Table 3
Breakdown of human urine samples of smokers and non-smokers analyzed for ATCA in this study
Urine samples

Number of samples
Male

Smokers
Non-smokers

8
15

ATCA concentration (ng/ml)
Female

Total

11
6

control occurred during the freeze-thaw and the long-term
stability experiments. It should be noted that the largest deviation for the long-term stability samples occurred in the 2nd
month, whereas in the 3rd month, all samples were found to
deviate by less than 5% of the control value. Also, the largest
deviation during the freeze-thaw experiments occurred on the
second freeze-thaw cycle compared with the third through
fifth freeze-thaw cycle of less than 5%. This indicates that
the deviation from the control is not associated with instability in ATCA concentrations, but more consistent with random
error in the overall analysis of ATCA.
3.6. Analysis of ATCA in human urine and blood
Applicability of the current analytical method for ATCA
analysis was achieved by analyzing human urine to determine concentrations of ATCA in non-smoking and smoking
human volunteers. Prior attempts to determine ATCA concentrations in non-smokers have failed to determine concentrations above the detection limit of the analytical method
[14]. Fig. 4 shows the GC–MS chromatograph of urine in
a male non-smoker without ATCA-d2 . A significant ATCA(TMS)3 peak is evident in the urine of this subject and is
absent from the non-spiked synthetic urine, which indicates
that endogenous concentrations of ATCA can be determined
by the analytical method presented.
The urine of forty human volunteers was used to determine concentrations of ATCA in male (23 total) and female
(17 total) smokers and non-smokers. Reported in Table 3 is
a breakdown of the number of volunteers by smoker or nonsmoker and male or female. The mean and standard deviation
of ATCA concentrations analyzed in urine for each group are
also reported in Table 3. It is clear that the mean ATCA concentration increases for smokers as opposed to non-smokers
in each individual group. The difference in ATCA concentrations between smokers and non-smokers were tested for
significance with a two-tailed t-test. The difference was significant to the 99% confidence interval for the pooled data (all
samples, only differentiated by smoker or non-smoker). An
analysis of variance was performed on the data, broken down
into female non-smoker, female smoker, male non-smoker,
and male smoker to determine if there were significant differences between the groups indicated. It was determined
that there were significant differences between male smokers
compared with female smokers, male non-smokers compared
with female smokers, and female non-smokers compared
with female smokers. The ability of the analytical method to
determine a significantly elevated concentration of ATCA in
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Male

Female

Total

115 ± 36
87 ± 46

319 ± 284
80 ± 53

233 ± 237
85 ± 47

the urine of smokers relative to non-smokers (for the pooled
data) indicates that the analytical method presented will be
able to determine past exposure to higher doses of cyanide.
Although the analytical method can determine significant
differences between urinary ATCA concentrations of smokers versus non-smokers, the large concentration of endogenous ATCA found in urine may present a potential problem for using this analytical technique to verify exposure
to cyanide. Although this is a potential problem, it is mitigated by the fact that other markers of cyanide exposure
also suffer from this problem, and endogenous concentrations for other chemical agent markers have been addressed
in the past [20,21]. Endogenous concentrations of ATCA in
human plasma were found to be below the detection limit
for the method presented (Fig. 5), possibly allowing for the
definitive verification of exposure to cyanide.

4. Conclusions and perspectives
The current GC–MS method to determine ATCA in urine
and plasma is a sensitive and precise analytical method that
shows great promise to augment or replace current analytical
methods to determine past exposure to cyanide. This study
indicates that the method presented can be used with human
urine and plasma samples and can detect endogenous levels
of ATCA in the urine of non-smokers.
Future studies include a broad analysis of ATCA in human urine of smokers and non-smokers to further evaluate
the analytical method’s ability to determine ATCA in human urine samples and to establish approximate endogenous
concentrations of ATCA in human urine. These endogenous
concentrations will be used to help determine the validity of
using ATCA as a marker for verification of cyanide exposure.
Other directions include mapping endogenous concentrations
of ATCA in blood, animal tissues, and hair. Also, exposure of
animals to cyanide while monitoring ATCA concentrations
in blood and urine will be used to determine the difference
between endogenous ATCA concentrations and ATCA concentrations after exposure to cyanide.
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